evipedia.aiv0.1 Evidence-Based Reviews of Health & Longevity Interventions

Using Nattokinase to Improve Health and Longevity

Created on 03/23/2026 using AI4L / Claude Opus 4.6

Motivation

Nattokinase is a serine protease enzyme extracted from natto, a traditional Japanese food made from soybeans fermented with the bacterium Bacillus subtilis var. natto. First identified by Dr. Hiroyuki Sumi in 1987, nattokinase has attracted growing interest as a natural supplement with cardiovascular benefits, particularly for its fibrinolytic (clot-dissolving) and antihypertensive (blood-pressure-lowering) properties. In Japan and other parts of East Asia, natto consumption has been associated epidemiologically with lower cardiovascular mortality, prompting researchers to investigate whether nattokinase supplementation could offer similar protective effects in broader populations.

For adults aged 45–65 seeking to optimize cardiovascular health and longevity, nattokinase presents an intriguing option as a well-tolerated, over-the-counter supplement with a long history of dietary use. However, the evidence base is still maturing. While smaller RCTs (randomized controlled trials, studies where participants are randomly assigned to treatment or placebo) have shown meaningful blood pressure reductions, the largest and longest trial to date — the NAPS trial with 265 participants over 3 years — found no significant effect on atherosclerosis progression at standard doses. This review examines the current evidence, weighing both the promise and the limitations, to support informed decision-making.

See: Protocol - Conclusion

Key resources providing a high-level overview of nattokinase and its health applications.

Note: No directly relevant nattokinase-focused content was found from Rhonda Patrick or Chris Kresser. Peter Attia has mentioned nattokinase briefly in the context of DVT (deep vein thrombosis, a blood clot in a deep vein) prevention during travel, but this content is behind a paywall and not directly linkable.

Grokipedia

A search was performed on grokipedia.com for nattokinase.

  • Nattokinase

    Provides a balanced, AI-curated overview of nattokinase covering its enzymatic properties, cardiovascular research, dosing conventions, and safety profile, useful as a quick reference alongside primary literature.

Examine

A search was performed on examine.com for nattokinase.

  • Nattokinase

    Examine’s evidence-based supplement page aggregates human study data on nattokinase across multiple health outcomes including blood pressure, lipids, and blood clotting, with quality ratings for each outcome.

ConsumerLab

A search was performed on consumerlab.com for nattokinase.

  • Nattokinase Supplements Review

    ConsumerLab’s independent product review tests nattokinase supplements for enzyme activity, contamination, and label accuracy, and provides guidance on product selection and quality considerations.

Systematic Reviews

Systematic reviews and meta-analyses evaluating nattokinase for cardiovascular outcomes.

Note: This is currently the only systematic review or meta-analysis specifically examining nattokinase supplementation on PubMed. While other reviews of nattokinase exist, they are narrative reviews rather than systematic reviews and are cited elsewhere in this document.

Mechanism of Action

Nattokinase is a 275-amino-acid serine protease belonging to the subtilisin family of enzymes. Its primary mechanisms of action include:

  • Direct fibrinolysis: Nattokinase directly degrades fibrin, the protein mesh that forms the structural framework of blood clots. Unlike pharmaceutical thrombolytics that work through a single pathway, nattokinase cleaves fibrin cross-links at multiple sites.
  • Indirect fibrinolysis via tPA (tissue plasminogen activator, a protein that helps dissolve clots) enhancement: Nattokinase increases the body’s production of tPA, amplifying the endogenous (internally produced) fibrinolytic system.
  • PAI-1 (plasminogen activator inhibitor-1, a protein that suppresses clot breakdown) reduction: Nattokinase decreases levels of PAI-1, removing an inhibitor of the body’s natural clot-dissolving machinery.
  • Blood pressure regulation: Nattokinase inhibits ACE (angiotensin-converting enzyme, which narrows blood vessels and raises blood pressure), functioning similarly to ACE inhibitor medications but with considerably lower potency. It also modulates renin activity in the RAAS (renin-angiotensin-aldosterone system, the hormonal pathway that regulates blood pressure and fluid balance).
  • Lipid modulation: At higher doses (10,800 FU [fibrinolysis units, the standard measure of nattokinase enzyme activity] per day), nattokinase may reduce total cholesterol and LDL (low-density lipoprotein, often called “bad cholesterol”) through mechanisms not yet fully characterized, possibly involving enhanced hepatic lipid metabolism.
  • Antiplatelet activity: Nattokinase inhibits platelet aggregation (the clumping together of blood platelets), reducing the tendency of blood to form unwanted clots.

Historical Context & Evolution

Nattokinase has its origins in natto, a staple of the traditional Japanese diet dating back over a thousand years. The enzyme was first scientifically identified in 1987 by Dr. Hiroyuki Sumi at the University of Chicago, who observed that natto dissolved artificial fibrin clots placed in a petri dish far more efficiently than other enzymes he had tested. This discovery launched decades of research into nattokinase’s fibrinolytic properties.

Initially, nattokinase attracted interest purely for its clot-dissolving potential — a natural alternative to pharmaceutical thrombolytics. Over the following decades, research expanded to include antihypertensive effects (first demonstrated in animal models in the 1990s, then confirmed in human RCTs in the 2000s), lipid-lowering potential, and anti-atherosclerotic properties. The enzyme gained particular attention in the longevity and health optimization communities after epidemiological data suggested that regular natto consumption was associated with reduced cardiovascular mortality in Japanese populations.

In 2012, the Japan Nattokinase Association established the standardized FU measurement system to enable consistent dosing across supplements. The enzyme’s regulatory path advanced when the NSF (National Science Foundation) International in the United States evaluated its safety profile. Today, nattokinase is widely available as a dietary supplement and has progressed to Phase II clinical trials in the United States for atherothrombotic prevention.

Expected Benefits

High

Blood Pressure Reduction

A meta-analysis of 6 RCTs (Li et al., 2023; PMID 39076715) found that nattokinase supplementation significantly reduced both systolic and diastolic blood pressure. An earlier RCT by Kim et al. (2008; PMID 18971533) with 86 participants showed reductions of -5.55 mmHg SBP and -2.84 mmHg DBP at 2,000 FU/day over 8 weeks. Jensen et al. (2016; PMID 27785095) confirmed similar findings in a North American population, with more robust effects observed in males. The blood pressure reduction is mediated through ACE inhibition and modulation of renin activity.

Magnitude: SBP reduction of approximately 3–6 mmHg; DBP reduction of approximately 2–3 mmHg at doses of 2,000 FU/day.

Fibrinolytic Activity (Clot Dissolution)

Nattokinase’s ability to break down fibrin clots has been demonstrated in both in vitro (laboratory) and in vivo (living organism) studies. The enzyme directly cleaves fibrin and enhances the body’s endogenous fibrinolytic system by increasing tPA and decreasing PAI-1 levels. Multiple clinical studies have confirmed measurable reductions in fibrinogen and D-dimer (a blood marker indicating clot breakdown activity) levels following nattokinase supplementation. This effect forms the primary basis for nattokinase’s traditional use and its ongoing clinical investigation.

Magnitude: Significant reductions in fibrinogen and D-dimer levels observed; direct quantification varies by study, with fibrinolytic activity approximately four times that of plasmin on a molar basis in vitro.

Medium

Lipid Improvement (High-Dose Only) ⚠ Conflicted

A large clinical study by Chen et al. (2022; PMID 36072877) with 1,062 participants found that nattokinase at 10,800 FU/day significantly improved lipid profiles and reduced atherosclerotic plaque size over 12 months, with improvement rates ranging from 66.5% to 95.4%. However, the same study found nattokinase was ineffective at 3,600 FU/day. The Li et al. (2023) meta-analysis found that lower doses actually showed unfavorable lipid changes, with increased total cholesterol and LDL cholesterol at standard doses. This sharp dose-dependency creates conflicting evidence: high doses appear beneficial while standard doses may be neutral or even slightly unfavorable for lipid parameters.

Magnitude: At 10,800 FU/day, significant reductions in total cholesterol, LDL, and triglycerides (TG, a type of fat in the blood) with improvement rates of 66.5–95.4%. At ≤3,600 FU/day, no meaningful lipid benefit.

Antiplatelet and Antithrombotic Effects

Nattokinase inhibits thromboxane formation and platelet aggregation, contributing to its antithrombotic profile. While these effects have been demonstrated in both preclinical and small clinical studies, the magnitude is modest compared to pharmaceutical antiplatelet agents. The antithrombotic effect represents a complementary mechanism to fibrinolysis, offering a multi-pathway approach to reducing thrombotic risk.

Magnitude: Modest reduction in platelet aggregation markers; clinical significance of this magnitude of antiplatelet activity in healthy individuals remains to be fully established.

Low

Anti-Atherosclerotic Effect ⚠ Conflicted

Evidence on nattokinase’s effect on atherosclerosis is directly conflicted. The NAPS trial (Hodis et al., 2021; PMID 33843667) — a well-designed RCT with 265 participants followed for 3 years — found no effect of nattokinase (2,000 FU/day) on CIMT (carotid artery intima-media thickness, a measure of arterial wall thickening used to assess atherosclerosis progression) or carotid arterial stiffness in healthy low-risk individuals. In contrast, Chen et al. (2022) reported significant reductions in both CIMT and carotid plaque size at 10,800 FU/day in a higher-risk population. The discrepancy may be explained by differences in dosing (2,000 vs. 10,800 FU/day), baseline cardiovascular risk, and study design (RCT vs. observational).

Magnitude: Null effect at 2,000 FU/day in low-risk individuals (NAPS trial); significant CIMT reduction and plaque regression at 10,800 FU/day in the Chen et al. study.

Neuroprotective Effects

Preclinical studies suggest nattokinase may have neuroprotective properties, including the ability to degrade amyloid fibrils associated with Alzheimer’s disease. In vitro studies have shown nattokinase can break down amyloid-beta aggregates. However, these findings have not yet been validated in human clinical trials, and the ability of orally administered nattokinase to cross the blood-brain barrier in sufficient quantities remains uncertain.

Magnitude: Not quantified in available studies.

Speculative

Microplastic and Biofilm Degradation

Emerging interest in nattokinase’s proteolytic (protein-breaking) activity extends to its potential ability to degrade biofilms and fibrin-associated accumulations of microplastics in the body. Andrew Huberman has discussed this hypothesis, noting nattokinase’s broad-spectrum proteolytic capabilities. However, no controlled human studies have examined this application, and the hypothesis remains largely mechanistic and speculative.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in genes related to coagulation (e.g., Factor V Leiden, prothrombin G20210A) may influence how significantly an individual benefits from nattokinase’s fibrinolytic effects. Individuals with genetic predispositions to hypercoagulability may experience more noticeable benefit, though clinical data specific to nattokinase in these populations is lacking.
  • Baseline biomarker levels: Individuals with higher baseline blood pressure (pre-hypertension or stage 1 hypertension) show more pronounced blood pressure reductions than normotensive individuals. Similarly, those with elevated fibrinogen levels or higher baseline lipid values (at high doses) may experience greater benefit.
  • Sex-based differences: Jensen et al. (2016) found that blood pressure reductions were more robust in males, while females showed a more significant decrease in vWF (von Willebrand factor, a protein involved in blood clotting), suggesting sex-specific mechanisms of action.
  • Pre-existing health conditions: Individuals with pre-hypertension, mild hyperlipidemia, or elevated thrombotic risk markers stand to gain the most from supplementation. Those who are normotensive and at low cardiovascular risk — as in the NAPS trial — may see minimal benefit.
  • Age-related considerations: Older adults within the 45–65 range, who typically have higher baseline blood pressure and greater vascular stiffness, may experience proportionally greater benefit. However, the anticoagulant effect also requires more careful monitoring in older adults due to increased fall risk and potential for bleeding complications.

Potential Risks & Side Effects

High

Increased Bleeding Risk

As a fibrinolytic and antiplatelet agent, nattokinase inherently increases bleeding risk. This is the most clinically significant concern, particularly when combined with anticoagulant or antiplatelet medications. Case reports have documented subdural hematoma in a patient taking nattokinase with aspirin, and cerebellar hemorrhage in patients on concurrent anticoagulant therapy. Nattokinase should be discontinued at least 2 weeks before any surgical procedure.

Magnitude: Clinically significant bleeding events have been reported in case studies, particularly with concurrent use of anticoagulants or antiplatelet agents. In controlled studies without concurrent blood thinners, no notable adverse bleeding events were reported.

Medium

Interaction with Anticoagulant and Antiplatelet Medications

Nattokinase has additive effects with warfarin, heparin, aspirin, clopidogrel, and other blood-thinning agents. This synergistic anticoagulant effect can push individuals beyond their therapeutic INR (International Normalized Ratio, a measure of blood clotting time used to monitor warfarin therapy) range, significantly increasing bleeding risk. While Chen et al. (2022) found that aspirin co-administration produced a synergistic benefit under clinical supervision, unsupervised combination use is dangerous.

Magnitude: Case reports of serious hemorrhagic events with concurrent anticoagulant use. INR values can be unpredictably elevated.

Low

Gastrointestinal Discomfort

Some individuals may experience mild digestive symptoms including nausea, diarrhea, bloating, or stomach upset, particularly when starting nattokinase or at higher doses. These effects are generally transient and resolve with continued use or dose reduction.

Magnitude: Mild and self-limiting in most cases; reported in a small percentage of users across clinical trials.

Allergic Reactions (Soy-Derived Products)

Since nattokinase is derived from fermented soybeans, individuals with soy allergies may experience allergic reactions ranging from mild (hives, itching) to potentially severe (anaphylaxis). Some nattokinase products are now produced through recombinant technology and may not contain soy proteins, but this varies by manufacturer.

Magnitude: Rare but potentially serious in soy-allergic individuals. Most affected individuals are aware of their allergy prior to supplementation.

Hypotension Risk

Individuals who are already on antihypertensive medications or who have naturally low blood pressure may experience excessive blood pressure lowering with nattokinase supplementation. This can manifest as dizziness, lightheadedness, or fainting, particularly when standing up quickly.

Magnitude: Blood pressure reduction of 3–6 mmHg SBP may be clinically significant in individuals already at the lower end of normal ranges.

Speculative

Potential Vitamin K2 Depletion with Purified Products

Some nattokinase supplements (notably NSK-SD) are processed to remove vitamin K2, which is naturally present in natto. There is a theoretical concern that using vitamin-K2-depleted nattokinase long-term without separate K2 supplementation could miss the synergistic cardiovascular benefits that come from the combination of nattokinase and K2 as found in whole natto. Chen et al. (2022) found that co-administration with K2 produced improved outcomes.

Risk-Modifying Factors

  • Genetic polymorphisms: Individuals with genetic variants affecting coagulation (Factor V Leiden, prothrombin mutations) or those with hereditary bleeding disorders are at substantially higher risk of adverse bleeding events. CYP (cytochrome P450, a family of liver enzymes responsible for metabolizing many drugs) genetic variants that affect warfarin metabolism are relevant for those on concurrent warfarin therapy.
  • Baseline biomarker levels: Individuals with already-low platelet counts, prolonged bleeding times, or low blood pressure are at higher risk for adverse effects from nattokinase supplementation.
  • Sex-based differences: While no significant sex-based differences in adverse effects have been reported in clinical trials, the sex-specific mechanisms of action identified by Jensen et al. (2016) — particularly the vWF reduction in females — suggest potential for sex-dependent bleeding risk profiles that merit monitoring.
  • Pre-existing health conditions: Individuals with bleeding disorders, peptic ulcers, recent surgery, or stroke history are at elevated risk. Those with liver disease may have impaired coagulation factor production, compounding nattokinase’s anticoagulant effect. Individuals with low blood pressure or on antihypertensive medication face additive hypotension risk.
  • Age-related considerations: Adults at the older end of the 45–65 range have higher baseline fall risk, and any bleeding event — particularly intracranial — carries greater morbidity. Age-related decline in renal function may also affect the clearance of coagulation factors, potentially amplifying nattokinase’s effects.

Key Interactions & Contraindications

  • Prescription drug interactions:
    • Anticoagulants (warfarin, heparin, enoxaparin, rivaroxaban, apixaban): Additive anticoagulant effect; significantly increased bleeding risk
    • Antiplatelet agents (clopidogrel, prasugrel, ticagrelor): Enhanced antiplatelet activity; increased bleeding risk
    • Antihypertensive medications: Additive blood pressure lowering; may cause symptomatic hypotension
    • Thrombolytic agents (alteplase, tenecteplase): Dangerously enhanced fibrinolysis; contraindicated
  • Over-the-counter medication interactions:
    • Aspirin: Additive antiplatelet and anticoagulant effects; case reports of hemorrhagic events
    • NSAIDs (non-steroidal anti-inflammatory drugs, such as ibuprofen and naproxen, which reduce pain and inflammation): Increased bleeding risk due to combined antiplatelet activity
  • Supplement interactions:
    • Fish oil / omega-3 fatty acids: Mild additive antiplatelet effect
    • Garlic supplements: Additive anticoagulant and antiplatelet effects
    • Ginkgo biloba: Additive antiplatelet effect; increased bleeding risk
    • Vitamin E (high dose): Additive anticoagulant activity
    • Other fibrinolytic enzymes (serrapeptase, lumbrokinase): Additive fibrinolytic effect; combined use requires caution
  • Populations who should avoid nattokinase:
    • Individuals with active bleeding disorders or hemophilia
    • Those on therapeutic anticoagulation (especially warfarin or DOACs [direct oral anticoagulants, newer blood-thinning medications])
    • Patients within 2 weeks of scheduled surgery
    • Individuals with history of hemorrhagic stroke
    • Those with severe soy allergy (unless using a verified soy-free recombinant product)
    • Pregnant or breastfeeding women (insufficient safety data)

Risk Mitigation Strategies

  • Physician consultation before starting: Discuss nattokinase with a healthcare provider, especially if taking any blood-thinning medications or if you have a history of bleeding events. A baseline coagulation panel is advisable.
  • Start at a low dose: Begin with 2,000 FU/day and monitor for any signs of unusual bruising, prolonged bleeding from cuts, nosebleeds, or blood in stool/urine before considering dose escalation.
  • Avoid concurrent use with anticoagulants: Do not combine nattokinase with warfarin, DOACs, or heparin without explicit medical supervision. If combining with aspirin, do so only under physician guidance.
  • Pre-surgical discontinuation: Stop nattokinase at least 14 days before any planned surgical or dental procedure and inform your surgical team of its use.
  • Monitor blood pressure: If taking antihypertensive medications, monitor blood pressure more frequently when starting nattokinase to detect additive hypotensive effects early.
  • Choose quality products: Select supplements that are third-party tested, have standardized FU activity, and clearly label whether vitamin K2 has been removed (relevant for those on warfarin, as K2 can counteract warfarin’s effects).

Therapeutic Protocol

The most commonly studied and recommended protocol for nattokinase supplementation is as follows:

  • Standard dose: 2,000 FU (approximately 100 mg) per day, taken as a single dose. This is the dose used in the majority of clinical trials and is the baseline recommendation from the Japan Nattokinase Association (JNKA).
  • Higher dose for cardiovascular benefit: Chen et al. (2022) found significant atherosclerotic and lipid-lowering benefits at 10,800 FU/day, though this represents a substantially higher dose than the standard recommendation. Escalation to higher doses should be done gradually and under medical supervision.
  • Timing: Best taken on an empty stomach (at least 30 minutes before meals or 2 hours after) to maximize enzyme absorption. Some practitioners recommend evening dosing to align with the body’s natural increase in coagulation activity during nighttime hours, when cardiovascular events are most likely to occur.
  • Half-life: The fibrinolytic activity of nattokinase has been observed to persist for 8–12 hours following a single oral dose, supporting once-daily dosing for the standard protocol.
  • Single vs. split dosing: At the standard dose of 2,000 FU/day, a single dose is typical. For higher doses (e.g., 10,800 FU/day), splitting into 2–3 divided doses taken throughout the day is advisable to maintain more consistent fibrinolytic activity and reduce the risk of gastrointestinal discomfort.
  • Genetic polymorphisms: No specific pharmacogenomic guidance exists for nattokinase dosing. However, individuals with Factor V Leiden or other prothrombotic mutations should consult with a physician, as they may both benefit more from and be at higher risk for complications with nattokinase therapy.
  • Sex-based differences: Males may experience more pronounced blood pressure reductions, while females may see greater effects on vWF levels. These differences do not currently warrant different dosing protocols but may inform monitoring priorities.
  • Age-related considerations: Older adults (closer to 65) should start at the lower end of dosing and exercise greater caution due to increased bleeding risk and potential for drug interactions with age-related polypharmacy.
  • Baseline biomarker levels: Those with elevated blood pressure (≥130/85 mmHg) or elevated fibrinogen levels are most likely to see measurable benefit. Individuals with normal blood pressure and low cardiovascular risk may not experience meaningful changes, as suggested by the NAPS trial.
  • Pre-existing health conditions: Those with any bleeding tendency, liver disease, or kidney impairment should use nattokinase only under medical supervision and at reduced doses.

Discontinuation & Cycling

Nattokinase is generally considered suitable for long-term, continuous use based on the available safety data from clinical trials lasting up to 3 years (the NAPS trial). There are no known withdrawal effects upon discontinuation. The enzyme’s fibrinolytic activity will diminish within 12–24 hours of the last dose as nattokinase is cleared from the body.

No evidence currently supports cycling (periodic on/off periods) as necessary for maintaining efficacy. The enzyme does not appear to produce tolerance or tachyphylaxis (reduced response over time). However, some practitioners suggest periodic reassessment (every 6–12 months) of the continued need for supplementation based on updated bloodwork and cardiovascular risk assessment.

If discontinuation is planned before surgery, a washout period of at least 14 days is recommended to allow coagulation parameters to fully normalize.

Sourcing and Quality

  • Standardization: Look for products standardized to FU activity. The standard dose of 2,000 FU should be clearly stated on the label. Avoid products that list only milligrams without FU specification, as enzyme activity varies by manufacturing process.
  • Third-party testing: Choose products verified by independent testing organizations such as NSF International, USP (United States Pharmacopeia, a nonprofit organization that sets quality standards for supplements and medications), or ConsumerLab. These verify enzyme activity, purity, and absence of contaminants.
  • Vitamin K2 content: Some products retain the naturally occurring vitamin K2 from the natto fermentation process, while others (notably NSK-SD, a patented nattokinase formulation) have K2 removed. For individuals on warfarin, the K2-free version is essential to avoid interference with anticoagulation therapy. For others, the version with K2 may offer additional cardiovascular benefits.
  • Soy allergen considerations: Most nattokinase is derived from soy fermentation and will contain trace soy proteins. Individuals with soy allergies should seek products that specifically certify soy-protein-free status or look for recombinant nattokinase products.
  • Reputable brands: Doctor’s Best, Jarrow Formulas, NOW Foods, Source Naturals, and Allergy Research Group all produce nattokinase supplements that have undergone third-party testing. NSK-SD (produced by Japan Bio Science Laboratory) is the most extensively studied branded form.
  • Storage: Nattokinase supplements should be stored in a cool, dry place. Some formulations require refrigeration to maintain enzyme activity — check label instructions.

Practical Considerations

  • Time to effect: Blood pressure reductions have been observed within 4–8 weeks of consistent daily supplementation at 2,000 FU/day. Fibrinolytic effects (reduced fibrinogen, D-dimer) may be measurable within 2–4 weeks. Anti-atherosclerotic effects, if achievable, require months to years of consistent high-dose use.
  • Common pitfalls:
    • Taking nattokinase with meals, which can reduce enzyme absorption due to degradation by stomach acid and digestive proteases
    • Combining nattokinase with blood thinners without medical supervision
    • Expecting meaningful results at standard doses (2,000 FU/day) for lipid improvement or atherosclerosis, where the evidence suggests much higher doses (10,800 FU/day) may be required
    • Failing to discontinue before surgical procedures
    • Confusing nattokinase with natto — eating natto provides nattokinase plus vitamin K2, fiber, and other nutrients, but the nattokinase dose is variable and unpredictable
  • Regulatory status: Nattokinase is classified as a dietary supplement in the United States and is not FDA (Food and Drug Administration, the U.S. agency that regulates food and drug safety)-approved for the treatment of any disease. It is widely available without a prescription. In Japan, nattokinase-containing products may carry FOSHU (Foods for Specified Health Uses) certification.
  • Cost and accessibility: Nattokinase supplements are widely available and moderately priced, typically ranging from $15–30 for a 1–2 month supply at 2,000 FU/day. Higher-dose regimens will increase cost proportionally.

Interaction with Foundational Habits

  • Sleep: Nattokinase is unlikely to directly disrupt sleep. Some practitioners recommend evening dosing specifically because cardiovascular events peak during early morning hours, and nighttime nattokinase may provide protective fibrinolytic coverage during this vulnerable period. No studies have reported insomnia or sleep disruption as side effects.
  • Nutrition: Taking nattokinase on an empty stomach is recommended for optimal absorption. A diet high in vitamin K (leafy greens) will not interfere with nattokinase directly but is relevant for those also on warfarin. The DASH (Dietary Approaches to Stop Hypertension, an eating plan rich in fruits, vegetables, and low-fat dairy) diet and Mediterranean diet may provide complementary cardiovascular benefits. Consuming whole natto provides additional nutritional benefits (K2, protein, fiber) beyond isolated nattokinase.
  • Exercise: No known negative interactions with exercise. Regular physical activity was found by Chen et al. (2022) to further improve the outcomes of nattokinase supplementation on lipid and atherosclerosis parameters. However, individuals should be aware that intense exercise combined with nattokinase’s antiplatelet effects could theoretically increase bruising risk from contact activities.
  • Stress management: No direct interaction with cortisol (the body’s primary stress hormone) or the HPA (hypothalamic-pituitary-adrenal, the brain-adrenal gland axis that regulates stress response) axis has been documented. However, nattokinase’s modest blood pressure reduction may complement stress management practices that also lower blood pressure, such as meditation and deep breathing exercises.

Monitoring Protocol & Defining Success

Before starting nattokinase, obtain baseline lab work. Continue monitoring at the intervals specified below, particularly during the first 3–6 months.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure <120/80 mmHg Primary outcome for nattokinase benefit Measure at home; morning readings preferred; check seated and standing
Fibrinogen 200–300 mg/dL Assesses nattokinase’s fibrinolytic effect Fibrinogen = a blood-clotting protein; conventional range 200–400 mg/dL; fasting recommended
D-dimer <0.5 mg/L FEU Marker of active clot breakdown D-dimer = fibrin degradation product; elevated levels may indicate active thrombosis or excessive fibrinolysis
PT/INR PT 11–13.5 sec; INR 0.8–1.1 Safety check for excessive anticoagulation PT = prothrombin time; INR = International Normalized Ratio; critical if combining with any blood thinners
CBC with platelet count Platelets 150,000–400,000/μL Monitors for thrombocytopenia CBC = complete blood count; assess platelet adequacy for safe antiplatelet supplementation
Lipid panel TC <200, LDL <100, HDL >60, TG <100 mg/dL Monitors lipid effects at higher doses TC = total cholesterol; HDL = high-density lipoprotein (“good cholesterol”); relevant mainly for doses >3,600 FU/day
hs-CRP <1.0 mg/L Inflammatory marker; cardiovascular risk hs-CRP = high-sensitivity C-reactive protein (a marker of systemic inflammation); conventional range <3.0 mg/L

Monitoring frequency: Baseline labs before starting, repeat at 8 weeks, then every 6 months for ongoing use. Blood pressure should be monitored weekly during the first month.

Qualitative markers of success include stable or improved energy levels, absence of unusual bruising or bleeding, and no episodes of dizziness or lightheadedness suggesting excessive blood pressure reduction.

Emerging Research

Several ongoing clinical trials and emerging research directions may significantly advance our understanding of nattokinase:

  • NCT02080520 — The NAPS trial (Nattokinase Atherothrombotic Prevention Study) at the University of Southern California has completed and published results (Hodis et al., 2021; PMID 33843667). While the primary outcome was null for atherosclerosis at 2,000 FU/day, secondary analyses and the comprehensive biomarker data collected may yield additional insights.

  • NCT07229521 — A recruiting trial at Taipei Medical University examining the effects of nattokinase on cardiovascular disease risk factors, gut microbiota, sleep quality, and cognition in 80 participants. This trial is notable for its breadth of outcomes, potentially expanding the evidence base beyond traditional cardiovascular endpoints.

  • NCT06183307 — A recruiting trial in Brazil evaluating nattokinase’s effects on inflammation and cardiovascular risk in individuals with dyslipidemia (abnormal blood lipid levels). With 48 participants, this study may help clarify the dose-response relationship for lipid modification.

  • Dose-optimization research: The striking discrepancy between the null results of the NAPS trial at 2,000 FU/day and the positive findings of Chen et al. (2022) at 10,800 FU/day has spurred interest in determining the optimal effective dose. Future dose-ranging studies are needed to identify the minimum effective dose for different cardiovascular endpoints.

  • Microplastics and biofilm research: Growing public concern about microplastics in the body has generated interest in nattokinase’s broad proteolytic capabilities. While this application remains mechanistically plausible but clinically unproven, it represents a novel research direction that could expand nattokinase’s relevance beyond traditional cardiovascular use.

  • Combination therapy research: Chen et al. (2022) found synergistic effects when nattokinase was co-administered with vitamin K2 and aspirin. Further study of optimized combination protocols may improve clinical outcomes.

Conclusion

Nattokinase is a well-tolerated, naturally derived fibrinolytic enzyme with a robust evidence base supporting modest blood pressure reduction (approximately 3–6 mmHg SBP, 2–3 mmHg DBP) at standard doses of 2,000 FU/day. Its fibrinolytic, antiplatelet, and ACE-inhibitory properties provide a multi-mechanism approach to cardiovascular support that is particularly relevant for adults aged 45–65 seeking to complement foundational health habits.

However, the evidence for nattokinase must be interpreted with nuance. The largest and longest RCT (NAPS, n=265, 3 years) found no benefit for atherosclerosis progression at 2,000 FU/day in low-risk individuals, while a large observational study showed significant benefits at the substantially higher dose of 10,800 FU/day. This dose-dependency is a critical consideration: standard doses appear effective primarily for blood pressure and fibrinolytic endpoints, while higher doses may be needed for lipid and atherosclerotic benefits.

The primary safety concern is increased bleeding risk, which is inherent to nattokinase’s mechanism of action. This risk is manageable in otherwise healthy individuals but becomes clinically significant when combined with anticoagulant or antiplatelet medications. Anyone considering nattokinase should discuss it with their healthcare provider, particularly if they take blood-thinning medications or are planning surgery.

For the health-conscious adult with mildly elevated blood pressure or interest in cardiovascular risk reduction, nattokinase at 2,000 FU/day represents a reasonable, low-risk supplement with evidence-supported benefits for blood pressure and fibrinolytic activity. Those seeking broader cardiovascular benefits may consider higher doses under medical supervision, though the evidence base for high-dose protocols is less robust. As with all interventions, nattokinase works best as part of a comprehensive approach including diet, exercise, sleep optimization, and stress management.

See: Protocol